Argos Therapeutics Stock Price, News & Analysis (NASDAQ:ARGS)

$1.36 -0.01 (-0.73 %)
(As of 02/21/2018 04:00 PM ET)
Previous Close$1.36
Today's Range$1.33 - $1.41
52-Week Range$1.33 - $96.00
Volume505,961 shs
Average Volume960,016 shs
Market Capitalization$5.98 million
P/E Ratio-0.06
Dividend YieldN/A
Beta0.99

About Argos Therapeutics (NASDAQ:ARGS)

Argos Therapeutics logoArgos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company's Arcelis technology platform utilizes biological components from a patient's own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

Receive ARGS News and Ratings via Email

Sign-up to receive the latest news and ratings for ARGS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:ARGS
CUSIPN/A
Phone+1-919-2876300

Debt

Debt-to-Equity Ratio-1.46%
Current Ratio2.29%
Quick Ratio2.29%

Price-To-Earnings

Trailing P/E Ratio-0.0605790645879733
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$950,000.00
Price / Sales8.79
Cash FlowN/A
Price / CashN/A
Book Value$2.99 per share
Price / Book0.45

Profitability

Trailing EPS($22.45)
Net Income$-53,020,000.00
Net Margins-13,750.64%
Return on EquityN/A
Return on Assets-120.95%

Miscellaneous

Employees122
Outstanding Shares6,140,000

Argos Therapeutics (NASDAQ:ARGS) Frequently Asked Questions

What is Argos Therapeutics' stock symbol?

Argos Therapeutics trades on the NASDAQ under the ticker symbol "ARGS."

When did Argos Therapeutics' stock split? How did Argos Therapeutics' stock split work?

Argos Therapeutics shares reverse split on Friday, January 19th 2018. The 1-20 reverse split was announced on Thursday, January 18th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2018. An investor that had 100 shares of Argos Therapeutics stock prior to the reverse split would have 5 shares after the split.

How were Argos Therapeutics' earnings last quarter?

Argos Therapeutics Inc (NASDAQ:ARGS) announced its quarterly earnings data on Wednesday, August, 9th. The biopharmaceutical company reported ($4.20) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($4.50) by $0.30. The biopharmaceutical company had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.10 million. View Argos Therapeutics' Earnings History.

Where is Argos Therapeutics' stock going? Where will Argos Therapeutics' stock price be in 2018?

3 equities research analysts have issued twelve-month price targets for Argos Therapeutics' shares. Their forecasts range from $24.00 to $24.00. On average, they expect Argos Therapeutics' share price to reach $24.00 in the next twelve months. View Analyst Ratings for Argos Therapeutics.

What are Wall Street analysts saying about Argos Therapeutics stock?

Here are some recent quotes from research analysts about Argos Therapeutics stock:

  • 1. According to Zacks Investment Research, "Argos Therapeutics is a biopharmaceutical company which focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis (TM) technology platform. Argos Therapeutics is based in Durham, United States. " (8/14/2017)
  • 2. Stifel Nicolaus analysts commented, "Argos reported 4Q16 numbers that included a net loss of $15.4 million and a cash & cash equivalents balance of $53.0 million. This is a time of transition for the company as last month, the IDMC recommended Argos discontinue their Phase III trial of AGS-003 in mRCC (ADAPT) based on futility. The trial is still ongoing while the company is reviewing preliminary data and determining the path forward. In the meantime, the company is reducing its workforce in an effort to conserve cash. However, since quarter's end, one of the company's lenders called its outstanding $23.1 million loan so Argos' current cash balance is closer to about $30 million. As a result of the reduced cash position, we are decreasing our target price from $1.40 to $1.20." (3/17/2017)
  • 3. FBR & Co analysts commented, "On the morning of February 22, Argos Therapeutics announced that the Independent Data Monitoring Committee (IDMC) recommended that the company’s pivotal Phase III ADAPT clinical trial of rocapuldencel-T (AGS-003) in combination with sunitinib (standard therapy) for the treatment of metastatic renal cell carcinoma (mRCC) be discontinued for futility based on its planned interim data analysis. The IDMC came to a conclusion that the study was unlikely to demonstrate a statistically significant improvement in overall survival (OS) in the combination treatment arm of rocapuldencel-T and sunitinib. The company is in the process of analyzing preliminary data from the trial, and its next steps involve discussing the data with the FDA." (2/23/2017)
  • 4. Needham & Company LLC analysts commented, "Argos announced that the pivotal Phase III ADAPT trial of rocapuldencel-T (AGS-003) in renal cell carcinoma (RCC) reached futility at a pre-specified interim analysis. The Independent Data Monitoring Committee (IDMC) has recommended discontinuation of the trial. Argos plans to leave the trial open pending further data review and FDA discussion, however, we view the likelihood of approval in RCC, our main valuation driver, as too uncertain. We are downgrading shares to Neutral." (2/22/2017)

Who are some of Argos Therapeutics' key competitors?

Who are Argos Therapeutics' key executives?

Argos Therapeutics' management team includes the folowing people:

  • Hubert Birner Ph.D., Independent Chairman of the Board (Age 51)
  • Jeffrey D. Abbey, President, Chief Executive Officer, Director (Age 54)
  • Richard Katz M.D., Chief Financial Officer, Vice President (Age 53)
  • Lori R. Harrelson, Vice President - Finance (Age 45)
  • John D. Menditto, Vice President - Corporate Communications & Investor Relations
  • Douglas C. Plessinger, Vice President - Medical and Clinical Affairs (Age 46)
  • Charles A. Nicolette Ph.D., Vice President - Research & Development, Chief Scientific Officer (Age 53)
  • Robert F. Carey, Director (Age 58)
  • Igor Krol, Director
  • Richard G. Morrison Ph.D., Director (Age 75)

How do I buy Argos Therapeutics stock?

Shares of Argos Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Argos Therapeutics' stock price today?

One share of Argos Therapeutics stock can currently be purchased for approximately $1.36.

How big of a company is Argos Therapeutics?

Argos Therapeutics has a market capitalization of $5.89 million and generates $950,000.00 in revenue each year. The biopharmaceutical company earns $-53,020,000.00 in net income (profit) each year or ($22.45) on an earnings per share basis. Argos Therapeutics employs 122 workers across the globe.

How can I contact Argos Therapeutics?

Argos Therapeutics' mailing address is 4233 TECHNOLOGY DR, DURHAM, NC 27704-2173, United States. The biopharmaceutical company can be reached via phone at +1-919-2876300.


MarketBeat Community Rating for Argos Therapeutics (ARGS)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  209 (Vote Outperform)
Underperform Votes:  117 (Vote Underperform)
Total Votes:  326
MarketBeat's community ratings are surveys of what our community members think about Argos Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Argos Therapeutics (NASDAQ:ARGS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.00
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $24.00$24.00$82.67$82.67
Price Target Upside: 206.83% upside206.83% upside956.85% upside956.85% upside

Argos Therapeutics (NASDAQ:ARGS) Consensus Price Target History

Price Target History for Argos Therapeutics (NASDAQ:ARGS)

Argos Therapeutics (NASDAQ:ARGS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/19/2017FBR & CoLower Price TargetMkt Perform -> Mkt Perform$40.00 -> $24.00HighView Rating Details
3/17/2017Stifel NicolausLower Price TargetHold$24.00HighView Rating Details
2/22/2017Needham & Company LLCDowngradeBuy -> HoldN/AView Rating Details
2/22/2017JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
6/20/2016Piper Jaffray CompaniesReiterated RatingOverweight$220.00N/AView Rating Details
4/19/2016Roth CapitalBoost Price TargetBuy$220.00 -> $360.00N/AView Rating Details
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$340.00 -> $240.00N/AView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Argos Therapeutics (NASDAQ:ARGS) Earnings History and Estimates Chart

Earnings by Quarter for Argos Therapeutics (NASDAQ:ARGS)

Argos Therapeutics (NASDAQ ARGS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017($2.00)$0.05 millionViewN/AView Earnings Details
8/9/2017Q2 2017($4.50)($4.20)$0.10 million$0.07 millionViewN/AView Earnings Details
5/10/2017Q1 2017($11.60)$0.11 millionViewN/AView Earnings Details
3/16/2017Q4 2016($7.40)$0.16 millionViewN/AView Earnings Details
11/14/2016Q3 2016($7.00)($6.40)$0.35 million$0.15 millionViewN/AView Earnings Details
8/10/2016Q2($8.60)($9.60)$0.16 million$0.49 millionViewListenView Earnings Details
5/12/2016Q1($11.20)($11.40)$0.10 million$0.15 millionViewListenView Earnings Details
3/29/2016Q4($17.60)($16.80)$1.12 million$0.07 millionViewListenView Earnings Details
11/16/2015Q315($18.40)($19.40)$0.12 million$0.16 millionViewListenView Earnings Details
8/12/2015Q215($16.00)($19.00)$1.32 million$0.11 millionViewListenView Earnings Details
5/14/2015Q115($16.20)($17.80)$0.40 million$0.18 millionViewListenView Earnings Details
3/30/2015Q314($15.60)($16.60)$0.62 million$0.30 millionViewN/AView Earnings Details
11/13/2014Q3 2014($13.00)($15.40)$0.80 million$0.40 millionViewN/AView Earnings Details
8/13/2014Q214($12.00)($12.20)$1.27 million$1.26 millionViewN/AView Earnings Details
5/13/2014Q114($10.80)($21.00)$1.26 million$0.80 millionViewN/AView Earnings Details
3/27/2014Q4 2013($68.40)($723.80)$2.60 million$0.72 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Argos Therapeutics (NASDAQ:ARGS) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Argos Therapeutics (NASDAQ:ARGS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Argos Therapeutics (NASDAQ ARGS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 28.21%
Insider Trades by Quarter for Argos Therapeutics (NASDAQ:ARGS)
Institutional Ownership by Quarter for Argos Therapeutics (NASDAQ:ARGS)

Argos Therapeutics (NASDAQ ARGS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/10/2018Jeffrey D AbbeyCEOSell124,987$0.16$19,997.92510,046View SEC Filing  
1/9/2018Charles A NicoletteInsiderSell100,250$0.16$16,040.00View SEC Filing  
1/9/2018Richard D KatzVPSell104,435$0.16$16,709.60193,959View SEC Filing  
1/3/2018Charles A NicoletteInsiderSell92,001$0.16$14,720.16View SEC Filing  
1/3/2018Jeffrey D AbbeyCEOSell114,702$0.16$18,352.32635,033View SEC Filing  
1/3/2018Lori R HarrelsonVPSell59,072$0.16$9,451.52295,310View SEC Filing  
1/3/2018Richard D KatzCFOSell101,228$0.16$16,196.48298,394View SEC Filing  
10/7/2016International S PharmstandardMajor ShareholderBuy31,704$4.73$149,959.92View SEC Filing  
9/29/2016International S PharmstandardMajor ShareholderBuy43,618$4.56$198,898.08View SEC Filing  
9/20/2016International S PharmstandardMajor ShareholderBuy41,259$4.77$196,805.43View SEC Filing  
9/19/2016International S PharmstandardMajor ShareholderBuy5,580$4.76$26,560.80View SEC Filing  
9/16/2016International S PharmstandardMajor ShareholderBuy52,512$4.77$250,482.24View SEC Filing  
9/1/2016International S PharmstandardMajor ShareholderBuy16,977$4.78$81,150.06View SEC Filing  
8/24/2016International S PharmstandardMajor ShareholderBuy67,371$4.52$304,516.92View SEC Filing  
8/22/2016International S PharmstandardMajor ShareholderBuy75,474$4.24$320,009.76View SEC Filing  
12/16/2015Andrei Vladimirovich PetrovDirectorBuy5,000$1.80$9,000.005,000View SEC Filing  
12/16/2015Joan WinterbottomInsiderBuy250$1.83$457.50View SEC Filing  
12/15/2015Alexey Alexandrovic VinogradovDirectorBuy2,000$2.15$4,300.002,000View SEC Filing  
12/2/2015Jeffrey D AbbeyCEOBuy1,000$3.89$3,890.006,293View SEC Filing  
11/24/2015Holle Philippe Marie Marce VanDirectorBuy10,000$4.28$42,800.0045,100View SEC Filing  
9/3/2015Holle Philippe Marie Marce VanDirectorBuy12,000$6.27$75,240.0025,100View SEC Filing  
9/1/2015Holle Philippe Marie Marce VanDirectorBuy5,000$6.26$31,300.0013,100View SEC Filing  
8/25/2015Jean LamarreDirectorBuy2,500$6.14$15,350.002,500View SEC Filing  
8/19/2015Jeffrey D AbbeyCEOBuy5,500$4.75$26,125.00View SEC Filing  
2/12/2014Deventer Sander VanDirectorBuy36,416$8.00$291,328.00View SEC Filing  
2/12/2014International S PharmstandardMajor ShareholderBuy1,275,000$8.00$10,200,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Argos Therapeutics (NASDAQ ARGS) News Headlines

Source:
DateHeadline
Argos Announces Issuance of Patent Covering the Foundation for Manufacturing its HIV ImmunotherapyArgos Announces Issuance of Patent Covering the Foundation for Manufacturing its HIV Immunotherapy
finance.yahoo.com - February 15 at 8:40 AM
A Daytraders Guide To FearA Daytrader's Guide To Fear
finance.yahoo.com - February 13 at 9:56 AM
Argos Therapeutics Inc (ARGS) Given Consensus Recommendation of "Hold" by BrokeragesArgos Therapeutics Inc (ARGS) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 2 at 1:36 AM
Where Argos Therapeutics Inc (NASDAQ:ARGS) Stands In Terms Of Earnings Growth Against Its IndustryWhere Argos Therapeutics Inc (NASDAQ:ARGS) Stands In Terms Of Earnings Growth Against Its Industry
finance.yahoo.com - January 31 at 10:17 AM
34 Biggest Movers From Friday - Benzinga34 Biggest Movers From Friday - Benzinga
www.benzinga.com - January 22 at 8:05 AM
Argos executes reverse stock splitArgos executes reverse stock split
finance.yahoo.com - January 19 at 3:43 PM
Argos Therapeutics (ARGS) Planes 1-for-20 Reverse Stock SplitArgos Therapeutics (ARGS) Planes 1-for-20 Reverse Stock Split
www.streetinsider.com - January 19 at 12:26 PM
Argos Therapeutics Inc (ARGS) Insider Charles A. Nicolette Sells 100,250 SharesArgos Therapeutics Inc (ARGS) Insider Charles A. Nicolette Sells 100,250 Shares
www.americanbankingnews.com - January 12 at 3:24 PM
Argos Therapeutics Inc (ARGS) CEO Sells $19,997.92 in StockArgos Therapeutics Inc (ARGS) CEO Sells $19,997.92 in Stock
www.americanbankingnews.com - January 12 at 3:24 PM
Richard D. Katz Sells 104,435 Shares of Argos Therapeutics Inc (ARGS) StockRichard D. Katz Sells 104,435 Shares of Argos Therapeutics Inc (ARGS) Stock
www.americanbankingnews.com - January 12 at 3:24 PM
Insider Selling: Argos Therapeutics Inc (ARGS) Insider Sells 92,001 Shares of StockInsider Selling: Argos Therapeutics Inc (ARGS) Insider Sells 92,001 Shares of Stock
www.americanbankingnews.com - January 5 at 3:14 PM
Richard D. Katz Sells 101,228 Shares of Argos Therapeutics Inc (ARGS) StockRichard D. Katz Sells 101,228 Shares of Argos Therapeutics Inc (ARGS) Stock
www.americanbankingnews.com - January 5 at 3:14 PM
Jeffrey D. Abbey Sells 114,702 Shares of Argos Therapeutics Inc (ARGS) StockJeffrey D. Abbey Sells 114,702 Shares of Argos Therapeutics Inc (ARGS) Stock
www.americanbankingnews.com - January 5 at 12:08 PM
Comparing Argos Therapeutics (ARGS) and ChemoCentryx (CCXI)Comparing Argos Therapeutics (ARGS) and ChemoCentryx (CCXI)
www.americanbankingnews.com - December 29 at 5:28 PM
Should You Worry About Argos Therapeutics Inc’s (NASDAQ:ARGS) CEO Pay?Should You Worry About Argos Therapeutics Inc’s (NASDAQ:ARGS) CEO Pay?
finance.yahoo.com - December 29 at 3:34 PM
ETFs with exposure to Argos Therapeutics, Inc. : December 22, 2017ETFs with exposure to Argos Therapeutics, Inc. : December 22, 2017
finance.yahoo.com - December 22 at 11:40 AM
One Thing To Consider Before Buying Argos Therapeutics Inc (NASDAQ:ARGS)One Thing To Consider Before Buying Argos Therapeutics Inc (NASDAQ:ARGS)
finance.yahoo.com - December 14 at 11:42 AM
Argos Therapeutics, Inc. (ARGS) Short Interest Down 41.4% in NovemberArgos Therapeutics, Inc. (ARGS) Short Interest Down 41.4% in November
www.americanbankingnews.com - December 14 at 3:10 AM
ETFs with exposure to Argos Therapeutics, Inc. : December 11, 2017ETFs with exposure to Argos Therapeutics, Inc. : December 11, 2017
finance.yahoo.com - December 11 at 3:33 PM
With 42.3% Earnings Growth Lately, Did Argos Therapeutics Inc (ARGS) Outperform The Industry?With 42.3% Earnings Growth Lately, Did Argos Therapeutics Inc (ARGS) Outperform The Industry?
finance.yahoo.com - December 5 at 11:48 AM
ETFs with exposure to Argos Therapeutics, Inc. : November 30, 2017ETFs with exposure to Argos Therapeutics, Inc. : November 30, 2017
finance.yahoo.com - November 30 at 3:33 PM
Argos Provides Financial Update - GlobeNewswire (press release)Argos Provides Financial Update - GlobeNewswire (press release)
globenewswire.com - November 28 at 8:07 AM
Ocera Therapeutics (OCRX) and Argos Therapeutics (ARGS) Critical ComparisonOcera Therapeutics (OCRX) and Argos Therapeutics (ARGS) Critical Comparison
www.americanbankingnews.com - November 27 at 4:28 PM
Argos Therapeutics (ARGS) & The Competition Critical ReviewArgos Therapeutics (ARGS) & The Competition Critical Review
www.americanbankingnews.com - November 25 at 11:32 AM
Argos Therapeutics (ARGS) CEO Jeff Abbey on Q3 2016 Results - Earnings Call Transcript - Seeking AlphaArgos Therapeutics' (ARGS) CEO Jeff Abbey on Q3 2016 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 15 at 2:33 AM
Argos Therapeutics (ARGS) Announces Update on Immunology Data from the Phase 3 ADAPT TrialArgos Therapeutics (ARGS) Announces Update on Immunology Data from the Phase 3 ADAPT Trial
www.streetinsider.com - November 14 at 2:13 AM
Edited Transcript of ARGS earnings conference call or presentation 13-Nov-17 1:30pm GMTEdited Transcript of ARGS earnings conference call or presentation 13-Nov-17 1:30pm GMT
finance.yahoo.com - November 14 at 2:13 AM
Argos Therapeutics Provides Update on Immunology Data from the Phase 3 ADAPT Trial Presented at the SITC 2017 Annual MeetingArgos Therapeutics Provides Update on Immunology Data from the Phase 3 ADAPT Trial Presented at the SITC 2017 Annual Meeting
finance.yahoo.com - November 11 at 9:32 AM
Short Interest in Argos Therapeutics, Inc. (ARGS) Rises By 106.7%Short Interest in Argos Therapeutics, Inc. (ARGS) Rises By 106.7%
www.americanbankingnews.com - November 11 at 3:40 AM
Argos Therapeutics reports 3Q lossArgos Therapeutics reports 3Q loss
finance.yahoo.com - November 10 at 1:49 PM
Argos Reports Third Quarter 2017 Financial Results and Operational Highlights - GlobeNewswire (press release)Argos Reports Third Quarter 2017 Financial Results and Operational Highlights - GlobeNewswire (press release)
globenewswire.com - November 9 at 5:13 PM
Comparing Argos Therapeutics (ARGS) and Its RivalsComparing Argos Therapeutics (ARGS) and Its Rivals
www.americanbankingnews.com - November 7 at 2:06 PM
Argos Therapeutics (ARGS) Receives Milestone Payment from LummyArgos Therapeutics (ARGS) Receives Milestone Payment from Lummy
www.streetinsider.com - November 6 at 10:02 PM
Argos Therapeutics to Report Third Quarter 2017 Financial Results and Operational Highlights on Thursday, November ... - GlobeNewswire (press release)Argos Therapeutics to Report Third Quarter 2017 Financial Results and Operational Highlights on Thursday, November ... - GlobeNewswire (press release)
globenewswire.com - November 6 at 5:00 PM
Financial Contrast: Argos Therapeutics (ARGS) vs. 3SBio (SSRX)Financial Contrast: Argos Therapeutics (ARGS) vs. 3SBio (SSRX)
www.americanbankingnews.com - November 4 at 3:20 AM
Financial Comparison: Argos Therapeutics (ARGS) & The CompetitionFinancial Comparison: Argos Therapeutics (ARGS) & The Competition
www.americanbankingnews.com - November 3 at 5:12 PM
Who Are The Major Shareholders Of Argos Therapeutics Inc (ARGS)?Who Are The Major Shareholders Of Argos Therapeutics Inc (ARGS)?
finance.yahoo.com - November 1 at 9:37 PM
Contrasting Argos Therapeutics (ARGS) & Its RivalsContrasting Argos Therapeutics (ARGS) & Its Rivals
www.americanbankingnews.com - October 31 at 9:00 AM
Argos Therapeutics, Inc. (ARGS) Short Interest Down 21.1% in OctoberArgos Therapeutics, Inc. (ARGS) Short Interest Down 21.1% in October
www.americanbankingnews.com - October 29 at 1:50 AM
Argos Therapeutics (ARGS) & Its Competitors Head to Head ComparisonArgos Therapeutics (ARGS) & Its Competitors Head to Head Comparison
www.americanbankingnews.com - October 28 at 5:32 AM
Financial Survey: Argos Therapeutics (ARGS) & The CompetitionFinancial Survey: Argos Therapeutics (ARGS) & The Competition
www.americanbankingnews.com - October 27 at 7:14 AM
Financial Comparison: Argos Therapeutics (ARGS) vs. VIVUS (VVUS)Financial Comparison: Argos Therapeutics (ARGS) vs. VIVUS (VVUS)
www.americanbankingnews.com - October 20 at 8:32 AM
Analyzing Sinovac Biotech (SVA) and Argos Therapeutics (ARGS)Analyzing Sinovac Biotech (SVA) and Argos Therapeutics (ARGS)
www.americanbankingnews.com - October 19 at 6:26 AM
NasdaqGM Healthcare Industry: A Deep Dive Into Argos Therapeutics Inc (ARGS)NasdaqGM Healthcare Industry: A Deep Dive Into Argos Therapeutics Inc (ARGS)
finance.yahoo.com - October 18 at 10:19 PM
Head-To-Head Contrast: VIVUS (VVUS) and Argos Therapeutics (ARGS)Head-To-Head Contrast: VIVUS (VVUS) and Argos Therapeutics (ARGS)
www.americanbankingnews.com - September 30 at 6:26 AM
Argos Therapeutics Announces Appointment of Richard Morrison, PhD to Board of Directors - GlobeNewswire (press release)Argos Therapeutics Announces Appointment of Richard Morrison, PhD to Board of Directors - GlobeNewswire (press release)
globenewswire.com - September 28 at 8:03 AM
Argos Therapeutics (ARGS) Interim Analysis Of The Phase 3 Adapt Trial Evaluating Rocapuldencel - T (AGS-003) - SlideshowArgos Therapeutics (ARGS) Interim Analysis Of The Phase 3 Adapt Trial Evaluating Rocapuldencel - T (AGS-003) - Slideshow
seekingalpha.com - September 22 at 1:26 PM
Argos Therapeutics to Hold Conference Call to Discuss Update on the Phase 3 ADAPT Trial Presented at the ESMO ... - GlobeNewswire (press release)Argos Therapeutics to Hold Conference Call to Discuss Update on the Phase 3 ADAPT Trial Presented at the ESMO ... - GlobeNewswire (press release)
globenewswire.com - September 19 at 4:05 PM
Argos Therapeutics (ARGS) versus Vericel Corporation (VCEL) Head to Head ContrastArgos Therapeutics (ARGS) versus Vericel Corporation (VCEL) Head to Head Contrast
www.americanbankingnews.com - September 17 at 10:48 PM
Chiasma (CHMA) and Argos Therapeutics (ARGS) Critical ContrastChiasma (CHMA) and Argos Therapeutics (ARGS) Critical Contrast
www.americanbankingnews.com - September 15 at 6:28 PM

SEC Filings

Argos Therapeutics (NASDAQ:ARGS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Argos Therapeutics (NASDAQ:ARGS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Argos Therapeutics (NASDAQ ARGS) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.